CSL Coronavirus Information
We are committed to continuing to provide our medicines to patients around the world, while pursuing COVID-19 treatments through a variety of collaborations.
COVID-19: A Message from Our CEO
"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited
Watch Online: CoVIg-19 Plasma Alliance Featured on NBC News
In the race to find a treatment for COVID-19, the use of antibody-rich plasma from those who have recovered from the novel coronavirus to treat patients who are suffering from the illness has emerged as a hopeful potential therapy. CSL Behring is a key part of this effort.
The first phase is collecting plasma at licensed plasma collection centers across the U.S. from healthy individuals who have recovered from COVID-19.
News Releases & Updates
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
5 JUNE 2020: CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into a new, significant partnering agreement to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate which has been pioneered by researchers at UQ.
15 APRIL 2020: CSL continues to provide medicines to patients around the world.
CSL’s Global Role in Battling COVID-19
14 APRIL 2020: Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19.
CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
8 APRIL 2020: COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer.
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
6 APRIL 2020: Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.